IPOS
200005320-7

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 31/435

A1

(11) International Publication Number: WO 99/65486

(43) International Publication Date: 23 December 1999 (23.12.99)

(21) International Application Number: PCT/IB99/01117

(22) International Filing Date: 16 June 1999 (16.06.99)

(30) Priority Data:
60/089,469 16 June 1998 (16.06.98) US

(71) Applicant *(for all designated States except US)*: PFIZER PRODUCTS, INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: KE, Hua, Zhu [US/US]; 2 Deer Lane, Ledyard, CT 06339 (US); LI, Mei [CN/US]; 8 Seabury Lane, Westerly, RI 02891 (US); PAN, Lydia, Codetta [US/US]; 8 Schooner Drive, Mystic, CT 06355 (US); THOMPSON, David, Duane [US/US]; 37 Bittersweet Drive, Gales Ferry, CT 06355 (US).

(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., Patent Department, 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: THERAPEUTIC COMBINATIONS OF (SELECTIVE) ESTROGEN RECEPTOR MODULATORS (SERM) AND GROWTH HORMONE SECRETAGOGUES (GHS) FOR TREATING MUSCULOSKELETAL FRAILTY

(57) Abstract

This invention is directed to pharmaceutical combination compositions and methods containing (–)–cis–6–phenyl–5–(4–(2–pyrrolidin–1–yl–ethoxy)–phenyl)–5,6,7,8–tetrahydronaphthalene–2–ol or a pharmaceutically acceptable salt thereof and 2–amino–N–(2–(3a(R)–benzyl–2–methyl–3–oxo–2,3, 3a, 4,6,7–hexahydro–pyrazolo–[4,3–c]pyridin–5–yl)–1(R)–benzyloxymethyl–2–oxo–ethyl)–isobutyramide or a pharmaceutically acceptable salt thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass, frailty and low muscle mass.